Activity of trovafloxacin (CP-99,219) against Legionella isolates: In vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 314-319

  Edelstein, Paul H ^a,c   Edelstein, Martha A C ^a   Ren, Jianjun ^a   Polzer, Robert ^b   Gladue, Ronald P ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; ERYTHROMYCIN; OFLOXACIN; PRODRUG; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; GUINEA PIG; INTRAPERITONEAL DRUG ADMINISTRATION; LEGIONELLA PNEUMOPHILA; LUNG ALVEOLUS MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ERYTHROMYCIN; FLUOROQUINOLONES; GUINEA PIGS; HALF-LIFE; LEGIONELLA; LEGIONELLA PNEUMOPHILA; LEGIONELLOSIS; MACROPHAGES, ALVEOLAR; MALE; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; PRODRUGS;

EID: 0030071862     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.314     Document Type: Article

References (36)

1. Bertrand, A., F. Janbon, E. Despaux, O. Jonquet, and J. Reynes. 1987. L'ofloxacine (RU 43280). Etude clinique. Pathol. Biol. (Paris) 35:629-633.
2. Bouhaja, B., H. Thabet, L. Slim, F. Aissa, M. Amamou, and M. Yacoub. 1993 Pneumopathie communautaire mixte à Legionella pneumophila et Staphylococcus aureus Presse Med 22:1280 (Letter.)
3. Briggs-Gooding, B., and R. N. Jones. 1993. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob. Agents Chemother. 37:349-353.
4. Brighty, K. E., T. D. Gootz, A. E. Girard, R. Shanlter, M. J. Castaldi, D. Girard, S. A. Miller, and J. Faiella. 1995 Prodrugs of CP-99,219 for intravenous administration: synthesis and evaluation resulting in identification of CP-116,517, abstr. 730. In Program and abstracts of the 7th European Congress on Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases, Vienna.
5. Dournon, E., P. Rajagopalan, J. Vilde, and J. Pocidalo. 1986 Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J. Antimicrob. Chemother. 17(Suppl. B):41-48
6. Edelstein, P. H. 1981. Improved semiselective medium for isolation of Legionella pneumophila from contaminated clinical and environmental specimens J. Clin Microbiol. 14:298-303.
7. Edelstein, P. H. 1985 Legionnaires' disease laboratory manual, 3rd ed. National Technical Information Service, Springfield, Va.
8. Edelstein, P. H. 1995. Antimicrobial therapy for Legionnaires' disease, a review Clin. Infect. Dis. 21(Suppl. 3):S265-S276
9. Edelstein, P. H., K. Calarco, and V. K. Yasui. 1984. Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs. Am. Rev. Respir. Dis 130:849-856.
10. Edelstein, P. H., and M. A. C. Edelstein. 1989. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages. Antimicrob. Agents Chemother. 33:2132-2136.
11. Edelstein, P. H., and M. A. C. Edelstein. 1991. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob. Agents Chemother. 35:1811-181.
12. Edelstein, P. H., and M. A. C. Edelstein. 1992. In vitro activity of Ro 23-9424 against clinical isolates of Legionella species. Antimicrob. Agents Chemother. 36:2559-2561
13. Edelstein, P. H., and M. A. C. Edelstein. 1993. In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella species. Antimicrob. Agents Chemother. 37:908-910.
14. Edelstein, P. H., and M. A. C. Edelstein. 1994. In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Antimicrob. Agents Chemother. 38:200-204
15. Edelstein, P. H., M. A. C. Edelstein, and B. Holzknecht. 1992. In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L pneumophila pneumonia Antimicrob. Agents Chemother 36:2387-2391.
16. Edelstein, P. H., M. A. C. Edelstein, J. Weidenfeld, and M. B. Dorr. 1990. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 34:2122-2127.
17. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram positive bacteria. Antimiciob. Agents Chemother. 37:366-370.
18. Fitzgeorge, R. B., D. H. Gibson, R. Jepras, and A. Baskerville. 1985. Studies on ciprofloxacin therapy of experimental Legionnaires' disease. J Infect. 10:194-203
19. Gentry, L. O., B. Lipsky, M. O. Farber, B. Tucker, and G. Rodriguez-Gomez. 1992. Oral ofloxacin therapy for lower respiratory tract infection. South. Med J 85:14-18.
20. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens. Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216
21. Gladue, R. P., G. M. Bright, R. E. Isaacson, and M. F. Newborg. 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection Antimicrob. Agents Chemother 33:277-282.
22. Gootz, T. D., K. E. Brighty, M. R. Anderson, B. J. Schmieder, S. L. Haskell, J. A. Sutcliffe, M. J. Castaldi, and P. R. McGuirk. 1994. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthryridone antimicrobial. Diagn. Microbiol. Infect. Dis. 19:235-243.
23. Havlichek, D., L. Saravolatz, and D. Pohlod. 1987. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob. Agents Chemother. 31:1529-1534.
24. Johnson, J. D., W. L. Hand, J. B. Francis, N. King-Thompson, and R. W. Corwin. 1980. Antibiotic uptake by alveolar macrophages. J. Lab Clin Med. 95:429-439
25. Leroy, O., C. Beuscart, C. Chidiac, B. Sivery, E. Senneville, M. Vincent du Laurier, and Y. Mouton. 1989. Traitement des pneumonies dues aux légionelles, mycoplasmes, Chlamydiae et rickettsies par l'ofloxacine. Pathol. Biol. (Paris) 37:1137-1140.
26. Meyer, R. D. 1991. Role of the quinolones in the treatment of legionellosis. J Antimicrob. Chemother. 28:623-625.
27. Mouton, Y., O. Leroy, C. Beuscart, B. Sivery, E. Senneville, C. Chidiac, G. Beaucaire, and M. Vincent du Laurier. 1990. Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. J. Antimicrob Chemother. 26(Suppl. D):115-121.
28. Peugeot, R. L., B. A. Lipsky, T. M. Hooton, and R. E. Pecoraro. 1991. Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. Drugs Exp. Clin. Res. 17:253-257.
29. Pohlod, D. J., L. D. Saravolatz, and M. M. Somerville. 1988. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin. J. Antimicrob. Chemother. 22(Suppl. D):49-54.
30. Saito, A., H. Koga, H. Shigeno, K. Watanabe, K. Mori, S. Kohno, Y. Shigenu, Y. Suzuyama. K. Yamaguchi, and M. Hirota. 1986 The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs J. Antimicrob-Chemother 18:251-260
31. Saito, A., K. Sawatari, Y. Fukuda, M. Nagasawa, H. Koga, A. Tomonaga, H. Nakazato, K. Fujita, Y. Shigeno, and Y. Suzuyama. 1985. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob. Agents Chemother. 28:15-20.
32. Stamler, D. A., M. A. C. Edelstein, and P. H. Edelstein. 1994 Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob. Agents Chemother. 38:217-222
33. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of CP-99,219, a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394
34. Teng, R., T. G. Tesnfeldt, T. E. Liston, and G. Foulds. Unpublished data.
35. Vildé, J. L., E. Dournon, and P. Rajagopalan. 1986. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother. 30:743-748.
36. Wynckel, A., O. Toupance, J. P. Melin, C. David, S. Lavaud, T. Wong, D. Lamiable, and J. Chanard. 1991. Traitement des légionelloses par ofloxacine chez le transplante renal. Absence d'interférence avec la ciclosporine A. Presse Med. 20:291-293.